Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Avellino – page 4

67 clinical trials in Avellino, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Avellino at a glance
67
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

67 trials in Avellino

Open in trial search
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Study of Nous-209 Genetic Vaccine and Pembrolizumab for Patients with Advanced Microsatellite Instability-High Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:GAD20-209-FSP-A1
  • Sponsor:Nouscom S.r.l.

Study on Inupadenant, Carboplatin, and Pemetrexed for Adults with Metastatic Non-Small Cell Lung Cancer After Immunotherapy

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Inupadenant Hydrochloride
  • Sponsor:iTeos Belgium

Study on Ponatinib and Chemotherapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

EGFR gene mutation+1

Not recruiting

Study on the Effectiveness and Safety of BAY 2927088 Compared to Standard Treatment in Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BAY 2927088
  • Sponsor:Bayer AG

Study on Ponatinib and Blinatumomab for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Blinatumomab
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Follicular lymphoma

Not recruiting

Study of Mosunetuzumab and Zanubrutinib for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Mosunetuzumab
  • Sponsor:Fondazione Italiana Linfomi Ets

Hodgkin's disease

Not recruiting

Study of Atezolizumab and Drug Combination for Patients with Relapsed or Refractory Hodgkin's Lymphoma Eligible for Stem Cell Transplant

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Fondazione Italiana Linfomi Ets

Study on Prednisone and Vitamin D for Elderly Patients with Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Colecalciferol
  • Sponsor:Fondazione Italiana Linfomi Ets

Study of Niraparib and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Study on the Effectiveness and Safety of Osimertinib for Patients with EGFR Mutation-Positive Stage II-IIIB Non-Small Cell Lung Cancer After Tumor Removal

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib
  • Sponsor:AstraZeneca AB

Study on the Effects and Safety of Rilzabrutinib for Adults with Warm Autoimmune Hemolytic Anemia

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Rilzabrutinib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Avellino

What the registry says about research in the country

01 Oncology - Lung Cancer Research

Advanced research focusing on non-small cell lung cancer (NSCLC) treatments, including innovative combination therapies and targeted approaches for specific mutations.

  • Novel immunotherapy combinations
  • KRAS G12C mutation treatments
  • Targeted therapy evaluation

Multiple studies exploring the effectiveness of combinations of chemotherapy with newer therapeutic agents.

02 Colorectal Cancer Studies

Comprehensive research into metastatic colorectal cancer treatments, examining various therapeutic combinations and strategies.

  • Cetuximab-based therapies
  • Molecular-targeted treatments
  • Advanced stage interventions

Focus on improving treatment outcomes for patients with specific genetic profiles and advanced disease stages.

03 Hematologic Malignancies

Innovative trials in blood disorders and related cancers, including leukemia and lymphoma studies.

  • Acute Myeloid Leukemia treatments
  • Lymphoma therapy optimization
  • Novel drug combinations

Studies evaluating new therapeutic approaches for various blood cancers and related conditions.

04 Breast Cancer Research

Studies focusing on advanced breast cancer treatments, particularly in triple-negative and hormone-responsive cases.

  • Immunotherapy combinations
  • Endocrine therapy optimization
  • Treatment sequencing strategies

Research aimed at improving outcomes for different breast cancer subtypes.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.